Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate.

Authors: McCormick, David L; Rao, K V N; Johnson, William D; Bosland, Maarten C; Lubet, Ronald A; Steele, Vernon E

Published In Cancer Prev Res (Phila), (2010 Mar)

Abstract: To evaluate the potential efficacy of selenium and vitamin E as inhibitors of prostate carcinogenesis, four chemoprevention studies using a common protocol were done in a rat model of androgen-dependent prostate cancer. After stimulation of prostate epithelial cell proliferation by a sequential regimen of cyproterone acetate followed by testosterone propionate, male Wistar-Unilever rats received a single i.v. injection of N-methyl-N-nitrosourea (MNU) followed by chronic androgen stimulation via subcutaneous implantation of testosterone pellets. At 1 week post-MNU, groups of carcinogen-treated rats (39-44/group) were fed either a basal diet or a basal diet supplemented with l-selenomethionine (3 or 1.5 mg/kg diet; study 1), dl-alpha-tocopherol (vitamin E, 4,000 or 2,000 mg/kg diet; study 2), l-selenomethionine + vitamin E (3 + 2,000 mg/kg diet or 3 + 500 mg/kg diet; study 3), or selenized yeast (target selenium levels of 9 or 3 mg/kg diet; study 4). Each chemoprevention study was terminated at 13 months post-MNU, and prostate cancer incidence was determined by histopathologic evaluation. No statistically significant reductions in prostate cancer incidence were identified in any group receiving dietary supplementation with selenium and/or vitamin E. These data do not support the hypotheses that selenium and vitamin E are potent cancer chemopreventive agents in the prostate, and when considered with the recent clinical data reported in the Selenium and Vitamin E Cancer Prevention Trial (SELECT), show the predictive nature of this animal model for human prostate cancer chemoprevention.

PubMed ID: 20145190 Exiting the NIEHS site

MeSH Terms: Adenocarcinoma/chemically induced; Adenocarcinoma/pathology; Adenocarcinoma/prevention & control*; Alkylating Agents/toxicity; Androgens/administration & dosage; Animals; Antioxidants/pharmacology; Cyproterone Acetate/therapeutic use; Disease Models, Animal; Drug Therapy, Combination; Male; Methylnitrosourea/toxicity; Neoplasms, Hormone-Dependent/chemically induced; Neoplasms, Hormone-Dependent/pathology; Neoplasms, Hormone-Dependent/prevention & control*; Prostatic Neoplasms/chemically induced; Prostatic Neoplasms/pathology; Prostatic Neoplasms/prevention & control*; Rats; Rats, Wistar; Selenium Compounds/therapeutic use*; Selenomethionine/administration & dosage*; Testosterone/administration & dosage; Vitamin E/therapeutic use*; alpha-Tocopherol/therapeutic use

to Top